A quick look at the most recent new drug filings reveals how much interest there is in biologically derived molecules as therapeutic agents. The majority of the filings are for New Biological Entities rather than New Chemical Entities with the largest NBE group being Antibodies. As we move in this direction more and more data about the make up of these molecules, their degradation products, and improperly made versions are required. The need for this information about these complex systems makes efficient chromatographic separations very important to speeding up the development, quality control, and process monitoring of NBEs.
This presentation will look at new separation products designed to improve resolution and reproducibility in reverse phase separations. We will explore options for intact as well as reduced and digested proteins.
For Research Use Only. Not for use in diagnostic procedures.